South Korea-based clinical trial sample analysis leader GCCL and global contract research organization OPIS have signed a Memorandum of Understanding (MOU) to expand their collaboration and strengthen their footprint in the global clinical trial market. 

 

The agreement was announced on the sidelines of the 44th Annual JP Morgan Healthcare Conference 2026.

 

The partnership comes as multinational clinical trials surge, creating complex regulatory, clinical, and data challenges across regions. GCCL and OPIS plan to combine their expertise to deliver integrated solutions, streamlining clinical trial planning, sample analysis, and data management for biopharmaceutical companies in Europe and Asia.

 

At the signing ceremony, company representatives outlined plans to collaborate on joint global clinical trial services, co-develop projects, explore new business opportunities, and pursue additional initiatives.

 

GCCL aims to leverage the partnership to expand strategic relationships with global CROs, enhance integrated clinical trial solutions across Asia, Europe, and the Americas, and offer tailored services to a wider range of biopharmaceutical clients.

 

Giovanni Trolese, Vice President at OPIS, said, “This collaboration combines OPIS's Europe-focused global network with GCCL's clinical trial analysis expertise, creating a significant opportunity to deliver integrated and efficient clinical trial services to clients. We look forward to further expanding the global clinical trial network and continuously enhancing client-focused, innovative solutions through our close collaboration with GCCL.”

 

KwanGoo Cho, CEO of GCCL, added, “This MOU represents more than a partnership; it is a strategic collaboration to deliver optimized clinical trial solutions for global biopharmaceutical companies. By leveraging our close cooperation, we aim to maximize operational efficiency and provide tailored solutions to a diverse range of sponsors, generating tangible business synergies.”